# Evommune, Inc.: overview

EVMN · NYSE · CIK 2044725 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/evmn.md) · [Financials](/companies/evmn/financials.md) · [Filings](/companies/evmn/filings.md) · [Insiders](/companies/evmn/insiders.md)

Latest reported revenue: [$0](/filings/0001193125-26-337984.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-337984).

## Last eight quarters

| Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | [0.0 d](/filings/0001193125-26-093932.md) | [3.0](/filings/0001193125-26-211963.md) | [0.0](/filings/0001193125-26-337984.md) | [10.0](/filings/0001193125-25-315972.md) | [0.0 d](/filings/0001193125-26-093932.md) | [0.0](/filings/0001193125-26-211963.md) | [0.0](/filings/0001193125-26-337984.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | [(501.1%)](/filings/0001193125-26-211963.md) | not reported | [(133.3%)](/filings/0001193125-25-315972.md) | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | [(485.2%)](/filings/0001193125-26-211963.md) | not reported | [(124.8%)](/filings/0001193125-25-315972.md) | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(10.47)](/filings/0001193125-25-315972.md) | not reported | [(9.48)](/filings/0001193125-26-211963.md) | [(8.80)](/filings/0001193125-26-337984.md) | [(8.07)](/filings/0001193125-25-315972.md) | not reported | [(0.64)](/filings/0001193125-26-211963.md) | [(0.89)](/filings/0001193125-26-337984.md) |
| Free cash flow | $m | not reported | [(18.5) d](/filings/0001193125-26-093932.md) | [(23.9)](/filings/0001193125-26-211963.md) | [(26.2) d](/filings/0001193125-26-337984.md) | [(9.8) d](/filings/0001193125-25-315972.md) | [(16.8) d](/filings/0001193125-26-093932.md) | [(27.6)](/filings/0001193125-26-211963.md) | [(20.5) d](/filings/0001193125-26-337984.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: |
| Revenue | $m | [7.0](/filings/0001193125-26-093932.md) | [13.0](/filings/0001193125-26-093932.md) |
| Gross margin | % | not reported | not reported |
| Operating margin | % | [(1000.2%)](/filings/0001193125-26-093932.md) | [(623.6%)](/filings/0001193125-26-093932.md) |
| Net margin | % | [(954.4%)](/filings/0001193125-26-093932.md) | [(529.8%)](/filings/0001193125-26-093932.md) |
| Diluted EPS | $ per share | [(45.29)](/filings/0001193125-26-093932.md) | [(11.22)](/filings/0001193125-26-093932.md) |
| Free cash flow | $m | [(58.3)](/filings/0001193125-26-093932.md) | [(76.7)](/filings/0001193125-26-093932.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/evmn/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [EQT Fund Management S.a r.l.](/funds/1834239.md) | 2026-06-30 | $70.3m | 5,288,313 |  | Added +358,680 |
| [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $46.4m | 3,494,638 |  | Unchanged |
| [SymBiosis Capital Partners, LLC](/funds/2006045.md) | 2026-03-31 | $29.4m | 1,280,778 |  | Not compared |
| [Pivotal bioVenture Partners Investment Advisor LLC](/funds/1844645.md) | 2026-06-30 | $25.6m | 1,926,943 |  | Unchanged |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $23.4m | 1,553,132 |  | Added +93,712 |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $20.6m | 896,700 |  | Not compared |
| [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $20.0m | 1,502,235 |  | Unchanged |
| [Nan Fung Group Holdings Ltd](/funds/1782539.md) | 2026-06-30 | $19.2m | 1,441,032 |  | Unchanged |
| [Point72 Asset Management, L.P.](/funds/1603466.md) | 2026-06-30 | $19.1m | 1,435,049 |  | Added +1,398,472 |
| [ANDERA PARTNERS](/funds/1757283.md) | 2026-06-30 | $18.5m | 1,391,990 |  | Reduced −505,372 |

## Recent filings

[All 135 filings](/companies/evmn/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-01 | 12:01 ET | [8-K](/filings/0001193125-26-409865.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-409865 |
| 2026-09-23 | 20:05 ET | [8-K](/filings/0001193125-26-399378.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-399378 |
| 2026-09-15 | 12:30 ET | [8-K](/filings/0001193125-26-391390.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-391390 |
| 2026-09-09 | 22:05 ET | [8-K](/filings/0001193125-26-385430.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-385430 |
| 2026-08-06 | 20:09 ET | [10-Q](/filings/0001193125-26-337984.md) | Quarterly report, period 2026-06-30 | 0001193125-26-337984 |
| 2026-08-06 | 20:06 ET | [8-K](/filings/0001193125-26-337964.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-337964 |
| 2026-07-30 | 12:01 ET | [8-K](/filings/0001193125-26-324972.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-324972 |
| 2026-06-29 | 12:32 ET | [8-K](/filings/0001193125-26-286918.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-286918 |
| 2026-06-02 | 20:07 ET | [8-K](/filings/0001193125-26-253482.md) | 5.07 Shareholder vote results | 0001193125-26-253482 |
| 2026-05-07 | 20:16 ET | [10-Q](/filings/0001193125-26-211963.md) | Quarterly report, period 2026-03-31 | 0001193125-26-211963 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-093932.md), filed Mar 5, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/aa47f2fd-26a4-497b-bcaa-5013bdadbbfa)

## About the filer

- CIK: 2044725
- Tickers: EVMN
- Exchange: NYSE
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.